Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Autism, Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate-extended release, Methylphenidate-immediate release, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 7 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endometriosis Related Pain
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 43
States / cities: Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more

Conditions: Healthy Postmenopausal Women
Interventions: KSHN001034, Fulvestrant; Drug
Lead sponsor: Kashiv BioSciences, LLC; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: Age Related Cataracts
Interventions: EDTA Ophthalmic Solution 2.6%, EDTA Ophthalmic Solution 1.3%, Saline Solution (Placebo); Drug
Lead sponsor: Livionex Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: San Francisco, California • Overland Park, Kansas • Lutherville, Maryland + 3 more

Conditions: Sickle Cell Disease
Interventions: Aes-103, Placebo; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alcoholism
Interventions: Perampanel, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Farmington, Connecticut • New Haven, Connecticut • West Haven, Connecticut + 1 more

Conditions: Skin Ulcers, Sickle Cell Anemia
Interventions: Arginine Butyrate, Standard local care dressing; Drug · Other
Lead sponsor: Susan P. Perrine; Other
Eligibility: 16 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more

Conditions: Diabetic Nephropathy
Interventions: VPI-2690B low dose, VPI-2690B medium dose, Placebo to match VPI-2690B, VPI-2690B high dose; Drug
Lead sponsor: Vascular Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 32
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Mesa, California + 29 more

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: ampreloxetine; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 30 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 13
States / cities: Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more

Conditions: NY-ESO-1-expressing Tumors
Interventions: Vaccine only, Vaccine + cyclophosphamide; Biological
Lead sponsor: Hassane M. Zarour, MD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pain
Interventions: buprenorphine and low-dose naloxone, buprenorphine alone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: High Dose Resistance Exercise Training, Low Dose Resistance Exercise Training Group; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Ames, Iowa • Madison, Wisconsin

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate, Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 8 Years to 12 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: Vedolizumab IV, Vedolizumab SC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • Loma Linda, California • Orange, California + 10 more

Conditions: Knee Osteoarthritis
Interventions: Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose, Placebo comparator; Drug
Lead sponsor: Menarini Group; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 9
States / cities: Tucson, Arizona • Englewood, Colorado • DeLand, Florida + 5 more

Conditions: Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
Interventions: AL58805, AL8326, Eribulin, Fulvestrant; Drug
Lead sponsor: Advenchen Pharmaceuticals, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Maraviroc, Fosamprenavir, Ritonavir; Drug
Lead sponsor: Garden State Infectious Disease Associates, PA; Other
Eligibility: 18 Years to 64 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Voorhees Township, New Jersey

Conditions: Smoking Cessation
Interventions: Questionnaires, Low Dose Computed Tomography Scan, Shared Decision Making + Video, Cessation Counseling, Quitline, Pharmacotherapy Discussion, Nicotine Patch, Anti-Smoking Drug, Tobacco Treatment Program, Carbon Monoxide (CO) Level Test; Behavioral · Procedure · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years and older
Enrollment: 630 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HNSCC
Interventions: Cesium-131, Pembrolizumab; Device · Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 19 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Tobacco Use Cessation
Interventions: Varenicline, Nicotine Patch, Placebo Patch, Placebo Tablet, Questionnaires, Counseling Sessions, Lab Session, Saliva Test; Drug · Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
Interventions: Polypill, Usual Care (individual medications prescribed by primary cardiologist); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Fibromyalgia
Interventions: TNX-102 SL Tablet, 5.6 mg, Placebo SL Tablet; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 33
States / cities: Phoenix, Arizona • Oceanside, California • Santa Ana, California + 30 more

Conditions: Hypertension, Metabolic Syndrome
Interventions: Aliskerin/Valsartan and Rampiril; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Post-operative Pain
Interventions: Placebo, IV acetaminophen; Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Canton, Ohio

Search by objective public record fields.

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers

The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence

Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers

Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors

Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine

RESISTance Exercise for Depression Trial

Large-scale Brain Organization During Cognitive Control in ADHD

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee

A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer

Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

Polypill in Acute Coronary Syndrome

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

Efficacy of IV Acetaminophen for Pain Management